Corrigendum: Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis

Corrigendum: Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis

Bibliographic Details
Main Authors:	Maria do Carmo Vilas-Boas, Ana Patrícia Rocha, Márcio Neves Cardoso, José Maria Fernandes, Teresa Coelho, João Paulo Silva Cunha
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Neurology
Subjects:	ATTRv V30M amyloidosis polyneuropathy gait quantitative assessment ambulatory
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2022.980597/full

Similar Items

Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis
by: Maria do Carmo Vilas-Boas, et al.
Published: (2020-11-01)

Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy
by: S. S. Nikitin, et al.
Published: (2021-12-01)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
by: Laura Obici, et al.
Published: (2023-07-01)

Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy
by: Loris Poli, et al.
Published: (2023-10-01)

Portable RGB-D Camera-Based System for Assessing Gait Impairment Progression in ATTRv Amyloidosis
by: Maria do Carmo Vilas-Boas, et al.
Published: (2022-10-01)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
by: Hiroki Yamaguchi, et al.
Published: (2022-03-01)

Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
by: Morie Gertz, et al.
Published: (2020-09-01)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
by: Ivan Urits, et al.
Published: (2020-08-01)

Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
by: Maria Pedroto, et al.
Published: (2023-07-01)

Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area
by: Massimo Russo, et al.
Published: (2021-04-01)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
by: Volha Skrahina, et al.
Published: (2021-01-01)

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
by: Faruk Uğur Doğan, et al.
Published: (2019-03-01)

Hereditary transthyretin amyloidosis
by: T. A. Adyan, et al.
Published: (2020-01-01)

Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
by: David Adams, et al.
Published: (2021-10-01)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
by: Giampaolo Merlini, et al.
Published: (2020-02-01)

Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus
by: M. Grandis, et al.
Published: (2020-12-01)

Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
by: Lorenza Magliano, et al.
Published: (2021-04-01)

Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)
by: Fábio Fernandes, et al.
Published: (2024-07-01)

Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects
by: Massimo Russo, et al.
Published: (2020-12-01)

Characteristics of Patients with Hereditary Transthyretin Amyloid Polyneuropathy and Chronic Idiopathic Axonal Polyneuropathy in Russia: PRIMER Study Results
by: Natalya A. Suponeva, et al.
Published: (2025-01-01)

Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications
by: Marco Luigetti, et al.
Published: (2022-12-01)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
by: Ando Yukio, et al.
Published: (2013-02-01)

Case Report: Hereditary transthyretin (ATTRv) amyloidosis: The p.G103R mutation of the transthyretin gene in a Han Chinese family is associated with vitreous hemorrhage
by: Junhui Shen, et al.
Published: (2022-09-01)

A Clinical Case of the Hereditary Transthyretin Amyloidosis
by: E. V. Reznik, et al.
Published: (2021-05-01)

Clinical and biochemical characterization of hereditary transthyretin amyloidosis caused by E61K mutation
by: Xujun Chu, et al.
Published: (2022-10-01)

Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M
by: Hsueh-Wen Hsueh, et al.
Published: (2022-01-01)

Real-world tafamidis experience in hereditary transthyretin amyloidosis with peripheral neuropathy in Brazil
by: Luiz Felipe Pinto, et al.
Published: (2025-01-01)

Exploring Cardiac Sympathetic Denervation in Transthyretin-Mediated Hereditary Amyloidosis (ATTRv): Insights from <sup>123</sup>I-mIBG Scintigraphy
by: Maria Silvia De Feo, et al.
Published: (2025-02-01)

Skeletal Muscle Involvement Pattern of Hereditary Transthyretin Amyloidosis: A Study Based on Muscle MRI
by: Xujun Chu, et al.
Published: (2022-05-01)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
by: Vélez-Santamaría V, et al.
Published: (2022-12-01)

Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments
by: Arman Çakar, et al.
Published: (2017-09-01)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
by: Falcão de Campos C, et al.
Published: (2023-02-01)

Symptoms of Hereditary Transthyretin Amyloidosis: The Patient and Physician Perspective
by: Michael Lane, et al.
Published: (2024-09-01)

Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation
by: Stefano Tozza, et al.
Published: (2023-02-01)

Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis
by: Xiaochen Lin, et al.
Published: (2021-02-01)

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement
by: Chafic Karam, et al.
Published: (2024-11-01)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
by: Alejandra González‐Duarte, et al.
Published: (2020-03-01)

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
by: Juan González-Moreno, et al.
Published: (2023-12-01)

Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area
by: Wang S, et al.
Published: (2022-06-01)

Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria
by: Teodora Chamova, et al.
Published: (2022-04-01)